✦ LIBER ✦

Suboptimal responses in chronic myeloid leukemia : Implications and management strategies

✍ Scribed by Elias Jabbour; Giuseppe Saglio; Timothy P. Hughes; Hagop Kantarjian

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 840 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26391

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular monitoring in chronic myeloid

Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications

✍ Elias Jabbour; Jorge E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome‐positive cells undetectable by cytogenetic evaluation

Prognostic implications of basophil diff

Prognostic implications of basophil differentiation in chronic myeloid leukemia

✍ Dr. Judah A. Denburg; George Browman 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB 👁 1 views

Early cytogenetic and molecular response

Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase : Long-term implications

✍ Alfonso Quintás-Cardama; Jorgé E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Intolerance to tyrosine kinase inhibitor

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia : Definitions and clinical implications

✍ Javier Pinilla-Ibarz; Jorge Cortes; Michael J. Mauro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

## Abstract Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region‐Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long‐t

Characterization of several leukemia-ass

Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

✍ Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Thomas Hauser; Anita Schmit 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 279 KB

## Abstract To design a specific immunotherapy for leukemia patients, the identification of leukemia‐associated antigens (LAAs) is a pivotal step. Antileukemic effects after hematopoetic stem cell transplantation for myeloid leukemias are observed and might be related to the recognition of LAAs. Us

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during